Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 CMIC Supports Avigan Production for Potential COVID-19 Treatment | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

CMIC Supports Avigan Production for Potential COVID-19 Treatment

Includes clinical trials and manufacturing of influenza antiviral drug for COVID-19 patients

By: Contract Pharma

Contract Pharma Staff

CMIC Holdings Co., Ltd. said its affiliate, CMIC Co., Ltd., a contract research organization (CRO) in Japan, is providing monitoring services for Avigan Tablet (favipiravir), a product that Fujifilm Toyama Chemical Co., Ltd. gained approval in Japan for manufacture and sale as an influenza antiviral drug, phase III clinical trial in Japan and will support for manufacturing the product as a contract development and manufacturing organization (CDMO).
 
Recently, Fujifilm announced the start of clinical trials of Avigan in Japan and overseas as one of the drug candidates for COVID-19. In addition, the Japanese government plans to stockpile two million treatment courses of Avigan, as part of the Japanese government’s emergency economic package.
 
Also, CMIC CMO Co., Ltd., a CDMO in Japan, will manufacture Avigan Tablet at their main plant to contribute to Fujifilm’s accelerated production schedule.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters